dihexa retracted paper controversy This morning, @novartis announced that del-brax met the primary and key secondary endpoints in the biomarker cohort of the Phase 1/2 FORTITUDE study. The results showed reductions in biomarkers associated with DUX4 Two and a half years
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3



























